BTIG downgraded Valeant Pharmaceuticals (NYSE: VRX) from Buy to Neutral.The firm noted: We believe Valeant needs to sever its relationship ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE